A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia


SPR001-204 will be a randomized, double-blind, placebo-controlled study that will evaluate the potential of tildacerfont to reduce GC burden in adult subjects with classic CAH who have lower limit of detection (LLD) ≤ A4 ≤ 1.5x upper limit of normal (ULN) and are on supraphysiologic doses of GC therapy. SPR001-204 will be the first study of tildacerfont to evaluate GC dose reduction. In addition, Study SPR001-204 will characterize clinical outcomes after up to 52 weeks of treatment with tildacerfont.

I'm interested

18 Years and over
This study is NOT accepting healthy volunteers

Congenital Adrenal Hyperplasia, Diabetes & Endocrine

Adrenal Disorder, CAH, Congenital Adrenal Hyperplasia, congenital adrenal hyperplasia

Kristin Boxwell -
Kyriakie Sarafoglou
Phase II
See this study on